SLC5A2 and type 2 diabetes mellitus: On the other hand, SGLT2 inhibitors and GLP1-R agonist was shown to be effective not only on the attenuation of GV but also on the reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes [54].